Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biologics Beckon: Biocon, Mylan Strike Deal; Combine To Take Teva, Sandoz Head-on

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - Prospects for strong growth in the global generic biologics space in the next 10 years has brought together the world's third-largest generic drug maker Mylan and India's biotechnology company Biocon. The two signed a comprehensive deal that will share development and certain other costs to bring biologic drugs to the market
Advertisement

Related Content

Mylan Chairman Robert Coury On Lipitor's Future and India/Japan Expansion: An Interview With PharmAsia News
Mylan Weighs "Big Bang Or Phased" Products Rollout In India; Significant Workforce Additions Planned
Mylan Weighs "Big Bang" Or "Phased" Products Rollout In India; Significant Workforce Additions Planned
Asia Spotlight: Biocon Chair Kiran Mazumdar Shaw On Global Biosimilar Regulations, Partnerships And Future Competition
Biocon Chairwoman Kiran Mazumdar Shaw On Global Biosimilar Regulations, Partnerships And Future Competition: An Interview With PharmAsia News (Part 1 of 2)
Pfizer, Biocon Brush Off Deal Talks As Speculative, But Is There Fire Behind The Smoke?
India Market Bug Bites Mylan As It Sets Sights On Stage-Wise Product Rollouts
After Abbott, India Market Bug Bites Mylan Too As It Sets Sights On Stage-wise Product Rollout
Amylin, India's Biocon Join Hands For Peptide-Based Diabetes Compound
Biocon Of India To License Two Molecules In Growth Bid
Advertisement
UsernamePublicRestriction

Register

SC072036

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel